Comparative analysis of immune-related adverse events among patients with melanoma on immune checkpoint inhibitors: a retrospective cohort study
- 24 July 2023
- journal article
- letter
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 189 (5) , 637-640
Abstract
In a large, multi-institutional cohort of 672 patients with melanoma, we examined the comparative incidence and severity of immune-related adverse events among patients receiving first-line immune checkpoint inhibitors. Comparing PD-1 inhibitors, nivolumab was associated with significantly lower risk of high-grade toxicity onset compared with pembrolizumab on unadjusted logistic regression analysis. Compared with pembrolizumab, use of the CTLA-4 inhibitor ipilimumab was associated with a significant increase in risk of gastrointestinal, but not endocrine and cutaneous toxicities.Keywords
Funding Information
- Officde of Scholarly Engagement, Harvard Medical School
This publication has 7 references indexed in Scilit:
- Immune‐related adverse events in cancer patients being treated with immune checkpoint inhibitorsEuropean Journal of Haematology, 2021
- Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysisClinical and Translational Oncology, 2021
- Molecular Pathways of Colon Inflammation Induced by Cancer ImmunotherapyCell, 2020
- Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced MelanomaJAMA Network Open, 2020
- Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab Combination Therapy vs Ipilimumab Monotherapy in Patients With Advanced Unresectable MelanomaJAMA Dermatology, 2019
- Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysisBMJ, 2018
- Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic reviewAnnals of Oncology, 2017